Achieving Innovation in CLL Care
Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
Live Web Broadcast on Friday, December 10, 2021, 11:30 AM–1:30 PM EST
Join CLL Society and PeerView Institute to hear the newest data on BTK inhibitors and CAR-T cell constructs in CLL Treatment during this ASH 2021 Symposium.
Continuous or fixed duration therapy with targeted agents (including BTK, PI3K, and BCL-2 inhibitors) in chronic lymphocytic leukemia (CLL) has overturned the decades-long consensus centered on immunochemotherapy and decisively become the new standard of care. This CME-certified live Seminars and Tumor Board event will feature a panel of leading CLL experts who, mimicking the collaborative nature of real-world tumor boards, will blend serial, case-based discussion with mini seminars designed to illustrate how fully integrating targeted therapeutics—including BTK, PI3K, and BCL-2 inhibitors, as well as novel antibodies—can improve care across the clinical spectrum of CLL. Panelists will cover important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies, therapeutic sequencing in progressive disease settings, safety management and distinctions among agent classes, the use of MRD assessment as a treatment tool, and next-generation and novel combinatorial strategies. Register to watch the webcast below!